J P Morgan Chase & Co set a €85.00 ($98.84) price target on MorphoSys AG (ETR:MOR) in a report issued on Wednesday. The firm currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on MOR. Independent Research GmbH set a €77.00 ($89.53) price target on shares of MorphoSys AG and gave the company a buy rating in a research report on Monday, August 7th. Commerzbank Ag set a €76.00 ($88.37) price target on shares of MorphoSys AG and gave the company a buy rating in a research report on Tuesday. Goldman Sachs Group, Inc. (The) set a €55.00 ($63.95) price target on shares of MorphoSys AG and gave the company a neutral rating in a research report on Tuesday, September 19th. Deutsche Bank AG set a €90.00 ($104.65) price target on shares of MorphoSys AG and gave the company a buy rating in a research report on Monday, October 30th. Finally, Berenberg Bank set a €85.00 ($98.84) price target on shares of MorphoSys AG and gave the company a buy rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. MorphoSys AG has a consensus rating of Buy and a consensus target price of €81.25 ($94.48).

MorphoSys AG (MOR) opened at €76.54 ($89.00) on Wednesday. MorphoSys AG has a 52-week low of €38.14 ($44.35) and a 52-week high of €82.13 ($95.50).

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/j-p-morgan-chase-85-00-price-target-for-morphosys-ag-mor/1695015.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.